Alterity Therapeutics Ltd 6-K, filed Sep 25, 2026
Alterity Therapeutics Ltd (ATHE)
About this 6-K
Alterity Therapeutics Ltd filed this 6-K on September 25, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Alterity Therapeutics Limited
(Name of Registrant)
Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
|
99.1 |
Date of AGM and Closing Date for Director Nominations |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
||
|
By: |
/s/ Julian Babarczy |
|
|
Julian Babarczy |
||
|
Chairman |
||
Date: September 25, 2026
Exhibit 99.1
25 September 2026
ASX Announcement
DATE OF AGM AND CLOSING DATE FOR DIRECTOR NOMINATIONS
Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) (Alterity or the Company) advises that, in accordance with ASX Listing Rule 3.13.1, its next Annual General Meeting (AGM) will be held at 11.00am (AEDT) on Friday 20 November 2026.
In addition, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Friday 2 October 2026. Any nominations must be received in writing no later than 5.00pm (AEST) on Friday 2 October 2026 at the Company’s registered office.
Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be provided to shareholders shortly. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company’s website at www.alteritytx.com.
For further information, please contact:
Abby Macnish Niven
CFO & Company Secretary
T: +61 3 9349 4906
E: cfo@alteritytx.com
Alterity Therapeutics Limited
Level 15, 500 Collins Street, Melbourne, VIC 3000 Australia
T: +61 (0)3 9349 4906 | www.alteritytx.com